Treprostinil palmitil inhalation powder has favorable safety, efficacy in PAH at 12 months

Among patients with pulmonary arterial hypertension, once-daily treprostinil palmitil inhalation powder for 12 months was well tolerated and improved four efficacy endpoints, according to interim data from an open-label extension study.“In everyday practice, clinicians are focused on optimizing therapy to help patients achieve the greatest benefit while maintaining tolerability and